Sanjiv Gupta, MD
Internal Medicine · Grayson, KYNPI 1487761243
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,875 of the $48,602 with a category attached, or 67.6%. 48 manufacturers reported payments, led by Novo Nordisk at 42.2% of the total. Reporting peaked in 2019 at $31,783 and has fallen 95.0% since, to $1,598 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 622 payments — averaging $78.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$20K
- Johnson & Johnson$18K
- AbbVie$2K
- GSK$911
- Biofire Diagnostics, LLC$820
- Pfizer$602
- plus $5K from 42 others
Across 15 payments — averaging $1026.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$15K
What the payments were for
- Consulting fees$8202%
- Speaking & faculty fees$32,87568%
- Travel & lodging$4,3419%
- Food & beverage$10,54122%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,602 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $115,561 |
| JardianceEmpagliflozin | 177 | $107,657 |
| EliquisApixaban | 327 | $102,495 |
| XareltoRivaroxaban | 72 | $74,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $41,728 |
| MounjaroTirzepatide | 33 | $38,090 |
| FarxigaDapagliflozin Propanediol | 65 | $35,478 |
| Nurtec OdtRimegepant Sulfate | 24 | $32,438 |
| InvokanaCanagliflozin | 30 | $31,369 |
| RybelsusSemaglutide | 28 | $30,283 |
| JanuviaSitagliptin Phosphate | 33 | $29,242 |
| ProliaDenosumab | 14 | $24,085 |
| SublocadeBuprenorphine | 11 | $21,530 |
| LinzessLinaclotide | 18 | $18,275 |
| EntrestoSacubitril/Valsartan | 32 | $14,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $20,487 | $145,844121 claims |
| PfizerEliquis, Nurtec Odt | $602 | $134,932351 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $247 | $117,973191 claims |
| Johnson & JohnsonXarelto, Invokana | $18,316 | $105,410102 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $911 | $63,42770 claims |
| Lilly USA, LLCMounjaro | $341 | $38,09033 claims |
| AstraZenecaFarxiga | $452 | $35,47865 claims |
| MerckJanuvia | $290 | $29,24233 claims |
| AmgenProlia | $315 | $24,08514 claims |
| Indivior Inc.Sublocade | $13 | $21,53011 claims |
| AbbVieLinzess | $2,205 | $18,27518 claims |
| NovartisEntresto | $285 | $14,70932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Grayson
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Kelley McIntyreLouisville$48K
- Justin CaseFlorence$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.